Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1173-1181

  Vangsted, Annette J ^a   Klausen, Tobias W ^b   Abildgaard, Niels ^c   Andersen, Niels F ^d   Gimsing, Peter ^e   Gregersen, Henrik ^f   Nexø, Bjørn A ^g   Vogel, Ulla ^h,i,j  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Mental Health Services CPH   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

^h NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

ⁱ TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^j ROSKILDE UNIVERSITY   (Denmark)

more..

Author keywords

Haplotype and outcome; IL1B; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CYTIDINE; GUANOSINE; THALIDOMIDE; THYMIDINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IL1B PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; NFKB1 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; RECOMBINANT PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE INTERLEUKIN 1BETA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PROGNOSIS; SURVIVAL; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DENMARK; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PYRAZINES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 80055101222     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1194-3     Document Type: Article

References (21)

1. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675-6682 (Pubitemid 44085624)
2. Vangsted AJ, Klausen TW, Gimsing P, Andersen NF, Abildgaard N, Gregersen H, Vogel U (2009) A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 94:1274-1281
3. Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U (2009) The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 43:539-545
4. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ, Rafie-Kolpin M, Hsieh CM, Kornman KS, Duff GW (2006) Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 15:519-529 (Pubitemid 43205418)
5. Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A, Zienolddiny S (2009) A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis 30:1186-1192
6. Vangsted A, Gimsing P, Klausen TW, Nexo BA,Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U (2007) Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 120:1036-1045 (Pubitemid 46214303)
7. Vangsted AJ, Soeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB (2010) No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with multiple myeloma. BMC Cancer 10:404
8. Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, Vogel U, Gimsing P (2010) Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol 85:209-216
9. Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexo BA, and Vogel UB (2010) The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP. Ann Hematol (in press
10. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
11. Saber AT, Nielsen LR, Dictor M, Hagmar L, Mikoczy Z, Wallin H (1998) K-ras mutations in sinonasal adenocarcinomas in patients occupationally exposed to wood or leather dust. Cancer Lett 126:59-65 (Pubitemid 28142972)
12. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA (1999) Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93:300-305 (Pubitemid 29019416)
13. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B (1998) Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 103:1152-1160 (Pubitemid 29012658)
14. Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Lust JA (2006) Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 26:83-95 (Pubitemid 43364045)
15. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13:35-45 (Pubitemid 38072133)
16. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Genin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, Andre F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170-1178
17. Song J, Lei FT, Xiong X, Haque R (2008) Intracellular signals of T cell costimulation. Cell Mol Immunol 5:239-247
18. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227-264 (Pubitemid 28411130)
19. Du Z, Wei L, Murti A, Pfeffer SR, Fan M, Yang CH, Pfeffer LM (2007) Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. J Cell Biochem 102:1087-1094 (Pubitemid 350220030)
20. Myeloma Trialists' Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020-1034
21. Khoo TL, Vangsted AJ, Joshua D, Gibson J (2011) Interferonalpha in the treatment of multiple myeloma. Curr Drug Targets 12:437-446